Direct Oral Anticoagulants: Quick Primer on When to Use and When to Avoid

Abstract

Direct oral anticoagulants (DOACs) have transformed the landscape of antithrombotic therapy in the past two decades. However, there is uncertainty about when they should or should not be used for treatment or prevention of thromboembolic events. DOACs have largely replaced warfarin for many patients with atrial fibrillation or venous thromboembolism who require anticoagulant therapy. In addition to noninferior efficacy, fewer drug–drug and food–drug interactions and improved convenience; DOACs have been shown to reduce the risk of intracranial hemorrhage. They have also received new indications compared with warfarin, such as cardiovascular risk reduction in patients with stable atherosclerotic diseases. However, there are some scenarios in which DOACs are associated with inferior efficacy or worse safety compared with standard treatment, such as warfarin. These include patients with mechanical heart valves, thrombotic antiphospholipid syndrome, and others. Although DOACs offer a streamlined and convenient option for the management of many patients with or at risk of thromboembolic events, their use should be avoided in certain high-risk scenarios. This minireview summarizes such conditions and those in which there is uncertainty for use of DOACs for particular diseases or particular patient subgroups.

 

MissingLinkText

Keywords

direct oral anticoagulant - anticoagulant - warfarin - thromboembolism - thrombosis

Introduction

Direct oral anticoagulants (DOACs), including factor Xa inhibitors and direct thrombin inhibitors, offer benefits such as fixed dosing, and no routine monitoring, and were reassuringly found in clinical trials to have a lower risk of intracranial bleeding,[1] [2] [3] compared with vitamin-K antagonists (VKAs). They are preferred for stroke prevention in atrial fibrillation (SPAF)[2] [3] [4] [5] [6] [7] [8] and for treating venous thromboembolism (VTE)[9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] in most patients and can be used safely and effectively for most such patients, if they meet criteria for durable anticoagulation.[29] However, they may be less effective or safe in specific conditions such as thrombotic antiphospholipid syndrome (APS)[30] [31] [32] [33] [34] [35] and mechanical heart valves,[36] [37] with uncertainties in other conditions, or patients with end-stage renal disease (ESRD).[38] [39] [40] This primer provides a succinct summary about when to use and when to be cautious about DOACs.

 

MissingLinkText

Conditions where Direct Oral Anticoagulants are Standard of Care

Current guidelines endorse DOACs for SPAF based on landmark trials.[4] [5] [6] [7] For stable patients with atrial fibrillation who have had acute coronary syndromes or recent percutaneous coronary intervention,[41] [42] [43] [44] [45] [46] a DOAC combined with a single antiplatelet agent like clopidogrel is recommended for the first 12 months.[47] In stable patients with chronic coronary disease (i.e., without percutaneous coronary intervention or acute coronary syndromes in the prior 12 months) who have an indication for anticoagulation, discontinuing antiplatelet therapy and continuing only a DOAC may be considered.[47] [48] [49] [50] DOACs are also reasonable to use in patients with atrial fibrillation and many types of valvular heart disease, including bioprosthetic valves,[51] [52] [53] with the exception of rheumatic heart disease (including moderate to severe mitral stenosis[54] [55]) and mechanical heart valves, which will be discussed subsequently. For VTE, DOACs are recommended for both acute management (after early use of heparin-based regimens, in case of using dabigatran or edoxaban),[9] [10] [11] [12] [13] including in cancer-associated thrombosis (except for dabigatran),[56] [57] [58] [59] [60] [61] [62] [63] and extended secondary prevention.[64] Additionally, in stable atherosclerotic cardiovascular disease[65] or after peripheral artery revascularization,[66] very low-dose rivaroxaban (2.5 mg twice daily) combined with aspirin has been shown to reduce cardiovascular events.

 

MissingLinkText

Conditions where Direct Oral Anticoagulants Should be Avoided

These benefits in the majority of patients notwithstanding, results of several recent randomized controlled trials (RCTs) have shown that DOACs may be less efficacious or safe compared with standard of care in scenarios such as mechanical heart valves, rheumatic atrial fibrillation (AF), thrombotic APS, post-transcatheter aortic valve replacement (TAVR) in those without another indication for anticoagulation, and embolic stroke of undetermined source (ESUS) ([Fig. 1]). Among patients with mechanical heart valves (including aortic, mitral and On-X valves), the use of DOACs was associated with a significantly higher risk of thromboembolic events and concern for higher risk of major bleeding compared with warfarin.[36] [37] Current guidelines recommend VKAs as a standard of care in patients with mechanical heart valves.[67] In turn, in patients with rheumatic heart disease and AF, DOACs led to an increased rate of a composite of stroke, systemic embolism, myocardial infarction, or death compared with VKAs, without a significant difference in the rate of major bleeds.[68] Several RCTs investigated the safety and efficacy of DOACs in patients with thrombotic APS compared with VKAs. However, individual results were limited by small samples and few events.[31] [32] [33] [34] [35] A prespecified meta-analysis of results from these RCTs showed that DOACs, compared with VKAs, resulted in a 5-fold excess risk of arterial thrombosis, including a 10-fold excess risk of stroke.[30] The results were consistent among patients with or without triple-positive APS, with or without history of arterial thrombosis, and in female and male patients alike.[30] In a pilot trial of patients with a left ventricular assist device, the use of dabigatran was associated with a higher rate of thromboembolic events.[69] Guidelines accordingly advise the use of VKAs compared with aspirin for all patients with left ventricular assist device.[70] Use of DOACs, compared with dual antiplatelet therapy, among patients in sinus rhythm who undergone TAVR has failed to show ischemic benefit, while in some studies (particularly with rivaroxaban) suggested harm with excess bleeding events and excess in death and thromboembolism.[71] [72] [73] [74] In patients with AF and recent TAVR, the use of edoxaban was noninferior to warfarin for the prevention of cardiovascular events; however, edoxaban was associated with higher risk of major bleeding, largely driven by gastrointestinal bleeds.[71] [75] Overall, in patients post-TAVR and no other indications for oral anticoagulants, existing guidelines recommend dual antiplatelet therapy for 3 to 6 months, followed by single antiplatelet therapy, with emerging evidence suggesting that early antiplatelet monotherapy being an attractive alternative. There is likely a role, however, for DOACs in patients undergoing TAVR who have a preexisting indication for anticoagulants.[75] The existing RCTs in patients with ESUS,[76] [77] [78] [79] including those that enrolled a broad population of patients with ESUS,[76] [77] or those targeted patients with predictive risk factors for AF,[78] or atrial cardiopathy defined as P-wave terminal force >5,000 µV.msecond⁻¹ in electrocardiogram lead V₁, serum N-terminal pro-B-type natriuretic peptide level >250 pg/mL, or left atrial diameter index ≥3 cm/m² on echocardiogram,[79] there has been no demonstrable benefit for DOACs compared with antiplatelet monotherapy. While future studies may identify a small subgroup that benefits from anticoagulation, the current best evidence is not supportive of their routine use.[80]

Fig. 1 Considerations of DOACs use across a spectrum of conditions and subgroups. *Other indications where DOACs should not be used include patients with TAVR and in sinus rhythm as well as patients with ESUS. ^†Apixaban has high levels in breast milk, but rivaroxaban and dabigatran have lower levels (see cited illustrated review for details[104]). ^‡In the absence of conditions summarized in the red zone and cautioning in the orange zone. ACHD, adult congenital heart disease; AF, atrial fibrillation; APS, antiphospholipid syndrome; CVST, central venous sinus thrombosis; DOACs, direct oral anticoagulants; DVT, deep vein thrombosis; ESRD, end-stage renal disease; ESUS, embolic stroke of undetermined source; LV, left ventricular; LVAD, left ventricular assist device; SPAF, stroke prevention in atrial fibrillation; TAVR, transcatheter aortic valve replacement; VTE, venous thromboembolism.

 

MissingLinkText

Uncertainties around Direct Oral Anticoagulants Use

Additionally, there are several indications and subgroups where the efficacy and safety of DOACs are uncertain.[81] [82] Recently, two large, randomized trials compared the role apixaban versus aspirin,[83] and edoxaban versus placebo,[84] in patients with atrial high rate episodes (also known as subclinical AF, lasting 6 minutes to 24 hours) detected by implantable cardiac monitors such as pacemakers. Results from both studies were directionally similar and reached significance for the apixaban trial,[83] and the pooled analysis of the two trials[85] for the reduction of the risk of ischemic stroke. However, the absolute event rates were low, precluding a practical use of DOACs in unselected patients. Ongoing studies from these trials can better inform practice about subgroups who may benefit from anticoagulation in this setting: in a subgroup analysis of the apixaban trial, patients with a CHA₂DS₂-VASc score >4 had a more favorable benefit-to-risk ratio, than those with CHA₂DS₂-VASc score <4.[86] While there has been concern about use of DOACs for preventing and treating left ventricular thrombus,[35] emerging data from multiple randomized trials,[87] [88] [89] [90] including the recently completed REWARF-STEMI trial and a resultant pooled analysis[91] [92] indicate that DOACs may be reasonable in this situation, until further data emerge. In a recent RCT comparing edoxaban versus warfarin in patients with chronic thromboembolic pulmonary hypertension who had undergone reperfusion treatment, edoxaban met criteria for noninferiority for a primary outcome of preventing worsening of pulmonary hemodynamics, and rates of recurrent VTE were not significantly different between both arms, although additional confirmatory data with other DOACs can further strengthen the evidence base.[93] Emerging evidence on DOACs use for cerebral venous sinus thrombosis suggest that their use may be reasonable: in a meta-analysis of randomized trials comparing DOACs (dabigatran and rivaroxaban) with VKAs for cerebral venous sinus thrombosis, there were similar rates of recurrent VTE, all-cause death, and recanalization in both groups.[94] [95] [96] [97] Several published and ongoing trials have investigated the use of DOACs for catheter-associated deep vein thrombosis[98] and splanchnic vein thrombosis,[99] but definitive evidence is lacking.

Pivotal RCTs for VTE management and SPAF have excluded patients with advanced renal disease or ESRD: limited data have shown that apixaban did not confer benefit, whereas dose-reduced rivaroxaban had hypothesis-generating impressive results in patients with AF and on dialysis.[38] [39] [40] The safety and efficacy of DOACs remain poorly studied among patients with a body mass index >45 kg/m², those weighing >150 kg, and those postbariatric surgery.[100] DOACs are also contraindicated in patients with advanced liver disease (Child-Pugh stage C), because of their partial hepatic clearance.[100] [101] In addition, the very elderly (patients older than 80 years) are underrepresented in most clinical trials of DOACs[103]—much like many other disease conditions. Recent evidence suggests that switching from VKAs to DOACs in patients with AF ≥ 75 years old who were stable on VKAs increased the risk of major bleeding compared with continuing with VKAs, without conferring additional benefits.[55] [104]

Similarly, given the limited data and concern for DOACs crossing the placenta, their use should be avoided in pregnancy. During breastfeeding, apixaban should be avoided, since it will have high levels in breast milk. While rivaroxaban and dabigatran are generally not advisable, they may have lower breast milk levels.[105]

 

MissingLinkText

Updates from the Major Guidelines in 2024

There are not currently any all-encompassing guidelines on the use of DOACs versus alternative treatment options in various conditions such as AF and VTE. The European Society of Cardiology recently published guidelines for the diagnosis and management of atrial fibrillation, recommending their use over VKAs for stroke prevention in AF, as well as in patients with AF and recent acute coronary syndrome or percutaneous intervention, and patients with AF and chronic coronary disease;[55] key exceptions include mechanical heart valves and rheumatic AF. They also include a IIb recommendation for considering DOACs in patients with subclinical AF and elevated thromboembolic risk, excluding patients at high risk of bleeding.[55] The European Society of Cardiology also recently released guidelines on the management of patients with peripheral arterial disease, where they suggest the use of very low-dose rivaroxaban (2.5 mg twice daily) with aspirin 75 to 100 mg daily for patients with chronic symptomatic peripheral arterial disease with or without revascularization,[106] recommendations shared as well by the American College of Cardiology/American Heart Association recent guide on the management of peripheral artery disease.[107]

In conclusion, DOACs are the cornerstone of therapy for SPAF and VTE prevention and treatment; however, they should be avoided in conditions such as thrombotic APS, mechanical heart valves, and rheumatic AF. Further research is needed to elucidate the potential mechanisms underlying their variable efficacy and safety in these scenarios and to find efficacious and safe treatment options for understudied populations such as those with cerebral vein thrombosis, splanchnic vein thrombosis, chronic thromboembolic pulmonary hypertension, and particularly those with cirrhosis,[108] advanced kidney disease[109] and ESRD.

 

MissingLinkText

 

MissingLinkText

Conflict of Interest

B.B. was supported by the Scott Schoen and Nancy Adams IGNITE Award and is supported by the Mary Ann Tynan Research Scientist award from the Mary Horrigan Connors Center for Women's Health and Gender Biology at Brigham and Women's Hospital, and the Heart and Vascular Center Junior Faculty Award from Brigham and Women's Hospital. B.B. reports that he was a consulting expert on behalf of the plaintiff for litigation related to two specific brand models of IVC filters. B.B. has not been involved in the litigation in 2022–2024, nor has he received any compensation in 2022–2024. B.B. reports that he is a member of the Medical Advisory Board for the North American Thrombosis Forum and serves in the Data Safety and Monitory Board of the NAIL-IT trial funded by the National Heart, Lung, and Blood Institute and Translational Sciences. B.B. is a collaborating consultant with the International Consulting Associates and the U.S. Food and Drug Administration in a study to generate knowledge about the utilization, predictors, retrieval, and safety of IVC filters. B.B. receives compensation as an Associated Editor for the New England Journal of Medicine Journal Watch Cardiology, as an Associate Editor for Thrombosis Research, and as an Executive Associate Editor for JACC, and is a Section Editor for Thrombosis and Haemostasis (no compensation). A.B. has no disclosures.

• References

• 1 Makam RCP, Hoaglin DC, McManus DD. et al. Efficacy and safety of direct oral anticoagulants approved for cardiovascular indications: systematic review and meta-analysis. PLoS One 2018; 13 (05) e0197583
• 2 Carnicelli AP, Hong H, Connolly SJ. et al; COMBINE AF (A Collaboration Between Multiple Institutions to Better Investigate Non-Vitamin K Antagonist Oral Anticoagulant Use in Atrial Fibrillation) Investigators. Direct oral anticoagulants versus warfarin in patients with atrial fibrillation: patient-level network meta-analyses of randomized clinical trials with interaction testing by age and sex. Circulation 2022; 145 (04) 242-255
• 3 Ruff CT, Giugliano RP, Braunwald E. et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014; 383 (9921) 955-962
• 4 Connolly SJ, Ezekowitz MD, Yusuf S. et al; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361 (12) 1139-1151
• 5 Patel MR, Mahaffey KW, Garg J. et al; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365 (10) 883-891
• 6 Granger CB, Alexander JH, McMurray JJ. et al; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365 (11) 981-992
• 7 Giugliano RP, Ruff CT, Braunwald E. et al; ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369 (22) 2093-2104
• 8 Connolly SJ, Eikelboom J, Joyner C. et al; AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med 2011; 364 (09) 806-817
• 9 Agnelli G, Buller HR, Cohen A. et al; AMPLIFY Investigators. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013; 369 (09) 799-808
• 10 Bauersachs R, Berkowitz SD, Brenner B. et al; EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363 (26) 2499-2510
• 11 Schulman S, Kearon C, Kakkar AK. et al; RE-COVER Study Group. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361 (24) 2342-2352
• 12 Büller HR, Décousus H, Grosso MA. et al; Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 2013; 369 (15) 1406-1415
• 13 Büller HR, Prins MH, Lensin AW. et al; EINSTEIN–PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012; 366 (14) 1287-1297
• 14 Agnelli G, Buller HR, Cohen A. et al; AMPLIFY-EXT Investigators. Apixaban for extended treatment of venous thromboembolism. N Engl J Med 2013; 368 (08) 699-708
• 15 Weitz JI, Lensing AWA, Prins MH. et al; EINSTEIN CHOICE Investigators. Rivaroxaban or aspirin for extended treatment of venous thromboembolism. N Engl J Med 2017; 376 (13) 1211-1222
• 16 Schulman S, Kearon C, Kakkar AK. et al; RE-MEDY Trial Investigators, RE-SONATE Trial Investigators. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med 2013; 368 (08) 709-718
• 17 Anderson DR, Dunbar M, Murnaghan J. et al. Aspirin or rivaroxaban for VTE prophylaxis after hip or knee arthroplasty. N Engl J Med 2018; 378 (08) 699-707
• 18 Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Hornick P. ; ADVANCE-2 investigators. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet 2010; 375 (9717) 807-815
• 19 Fuji T, Wang CJ, Fujita S. et al. Safety and efficacy of edoxaban, an oral factor Xa inhibitor, versus enoxaparin for thromboprophylaxis after total knee arthroplasty: the STARS E-3 trial. Thromb Res 2014; 134 (06) 1198-1204
• 20 Eriksson BI, Dahl OE, Rosencher N. et al; RE-MODEL Study Group. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007; 5 (11) 2178-2185
• 21 Lassen MR, Gallus A, Raskob GE, Pineo G, Chen D, Ramirez LM. ADVANCE-3 Investigators. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med 2010; 363 (26) 2487-2498
• 22 Eriksson BI, Dahl OE, Rosencher N. et al; RE-NOVATE Study Group. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007; 370 (9591) 949-956
• 23 Eriksson BI, Dahl OE, Huo MH. et al; RE-NOVATE II Study Group. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial. Thromb Haemost 2011; 105 (04) 721-729
• 24 Eriksson BI, Borris LC, Friedman RJ. et al; RECORD1 Study Group. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008; 358 (26) 2765-2775
• 25 Kakkar AK, Brenner B, Dahl OE. et al; RECORD2 Investigators. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 2008; 372 (9632) 31-39
• 26 Lassen MR, Ageno W, Borris LC. et al; RECORD3 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008; 358 (26) 2776-2786
• 27 Turpie AG, Lassen MR, Davidson BL. et al; RECORD4 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 2009; 373 (9676) 1673-1680
• 28 Ginsberg JS, Davidson BL, Comp PC. et al; RE-MOBILIZE Writing Committee. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty 2009; 24 (01) 1-9
• 29 Bikdeli B, Hogan H, Morrison RB. et al. Extended-duration low-intensity apixaban to prevent recurrence in patients with provoked venous thromboembolism and enduring risk factors: rationale and design of the HI-PRO Trial. Thromb Haemost 2022; 122 (06) 1061-1070
• 30 Khairani CD, Bejjani A, Piazza G. et al. Direct oral anticoagulants vs vitamin-K antagonists in thrombotic antiphospholipid syndrome: meta-analysis of randomized controlled trials. J Am Coll Cardiol 2023; 81 (01) 16-30
• 31 Cohen H, Hunt BJ, Efthymiou M. et al; RAPS trial investigators. Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial. Lancet Haematol 2016; 3 (09) e426-e436
• 32 Pengo V, Denas G, Zoppellaro G. et al. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood 2018; 132 (13) 1365-1371
• 33 Ordi-Ros J, Sáez-Comet L, Pérez-Conesa M. et al. Rivaroxaban versus vitamin K antagonist in antiphospholipid syndrome: a randomized noninferiority trial. Ann Intern Med 2019; 171 (10) 685-694
• 34 Woller SC, Stevens SM, Kaplan D. et al. Apixaban compared with warfarin to prevent thrombosis in thrombotic antiphospholipid syndrome: a randomized trial. Blood Adv 2022; 6 (06) 1661-1670
• 35 Bejjani A, Khairani CD, Assi A. et al. When direct oral anticoagulants should not be standard treatment: JACC State-of-the-Art Review. J Am Coll Cardiol 2024; 83 (03) 444-465
• 36 Eikelboom JW, Connolly SJ, Brueckmann M. et al; RE-ALIGN Investigators. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med 2013; 369 (13) 1206-1214
• 37 Wang TY, Svensson LG, Wen J. et al. Apixaban or warfarin in patients with an On-X mechanical aortic valve. NEJM Evid 2023; 2 (07) a2300067
• 38 Pokorney SD, Chertow GM, Al-Khalidi HR. et al; RENAL-AF Investigators. Apixaban for patients with atrial fibrillation on hemodialysis: a multicenter randomized controlled trial. Circulation 2022; 146 (23) 1735-1745
• 39 De Vriese AS, Caluwé R, Van Der Meersch H, De Boeck K, De Bacquer D. Safety and efficacy of vitamin K antagonists versus rivaroxaban in hemodialysis patients with atrial fibrillation: a multicenter randomized controlled trial. J Am Soc Nephrol 2021; 32 (06) 1474-1483
• 40 Reinecke H, Engelbertz C, Bauersachs R. et al. A randomized controlled trial comparing apixaban with the vitamin K antagonist phenprocoumon in patients on chronic hemodialysis: the AXADIA-AFNET 8 study. Circulation 2023; 147 (04) 296-309
• 41 Cannon CP, Bhatt DL, Oldgren J. et al; RE-DUAL PCI Steering Committee and Investigators. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med 2017; 377 (16) 1513-1524
• 42 Gibson CM, Mehran R, Bode C. et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med 2016; 375 (25) 2423-2434
• 43 Vranckx P, Valgimigli M, Eckardt L. et al. Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial. Lancet 2019; 394 (10206): 1335-1343
• 44 Lopes RD, Heizer G, Aronson R. et al; AUGUSTUS Investigators. Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation. N Engl J Med 2019; 380 (16) 1509-1524
• 45 Mega JL, Braunwald E, Mohanavelu S. et al; ATLAS ACS-TIMI 46 study group. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet 2009; 374 (9683) 29-38
• 46 Mega JL, Braunwald E, Wiviott SD. et al; ATLAS ACS 2–TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012; 366 (01) 9-19
• 47 Virani SS, Newby LK, Arnold SV. et al; Peer Review Committee Members. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA guideline for the management of patients with chronic coronary disease: a report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation 2023; 148 (09) e9-e119
• 48 Yasuda S, Kaikita K, Akao M. et al; AFIRE Investigators. Antithrombotic therapy for atrial fibrillation with stable coronary disease. N Engl J Med 2019; 381 (12) 1103-1113
• 49 Arashi H, Yamaguchi J, Hagiwara N. et al; AFIRE investigators. Rivaroxaban underdose for atrial fibrillation with stable coronary disease: the AFIRE trial findings. Thromb Haemost 2022; 122 (09) 1584-1593
• 50 Vrints C, Andreotti F, Koskinas KC. et al; ESC Scientific Document Group. 2024 ESC guidelines for the management of chronic coronary syndromes. Eur Heart J 2024; 45 (36) 3415-3537
• 51 Lip GYH, Collet JP, de Caterina R. et al. Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: Executive Summary of a Joint Consensus Document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, Endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE). Thromb Haemost 2017; 117 (12) 2215-2236
• 52 Renda G, Ricci F, Giugliano RP, De Caterina R. Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and valvular heart disease. J Am Coll Cardiol 2017; 69 (11) 1363-1371
• 53 Guimarães HP, Lopes RD, de Barros E Silva PGM. et al; RIVER Trial Investigators. Rivaroxaban in patients with atrial fibrillation and a bioprosthetic mitral valve. N Engl J Med 2020; 383 (22) 2117-2126
• 54 Joglar JA, Chung MK, Armbruster AL. et al; Peer Review Committee Members. 2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2024; 149 (01) e1-e156
• 55 Van Gelder IC, Rienstra M, Bunting KV. et al; ESC Scientific Document Group. 2024 ESC guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2024; 45 (36) 3314-3414
• 56 Mulder FI, Bosch FTM, Young AM. et al. Direct oral anticoagulants for cancer-associated venous thromboembolism: a systematic review and meta-analysis. Blood 2020; 136 (12) 1433-1441
• 57 Raskob GE, van Es N, Verhamme P. et al; Hokusai VTE Cancer Investigators. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med 2018; 378 (07) 615-624
• 58 Young AM, Marshall A, Thirlwall J. et al. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol 2018; 36 (20) 2017-2023
• 59 McBane II RD, Wysokinski WE, Le-Rademacher JG. et al. Apixaban and dalteparin in active malignancy-associated venous thromboembolism: the ADAM VTE trial. J Thromb Haemost 2020; 18 (02) 411-421
• 60 Agnelli G, Becattini C, Meyer G. et al; Caravaggio Investigators. Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med 2020; 382 (17) 1599-1607
• 61 Bikdeli B, Jiménez D. Safety of apixaban for cancer-associated thrombosis. Thromb Haemost 2021; 121 (05) 547-551
• 62 Sueta D, Yamashita Y, Morimoto T. et al; COMMAND VTE Registry-2 Investigators. Edoxaban, rivaroxaban, or apixaban for cancer-associated venous thromboembolism in the real world: insights from the COMMAND VTE Registry-2. Thromb Haemost 2024; 124 (11) 1013-1023
• 63 Pastori D, Palareti G. Open issues in the choice and management of direct oral anticoagulants in patients with cancer-related venous thromboembolism. Thromb Haemost 2024; 124 (11) 1024-1026
• 64 Konstantinides SV, Meyer G, Becattini C. et al; ESC Scientific Document Group. 2019 ESC guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J 2020; 41 (04) 543-603
• 65 Eikelboom JW, Connolly SJ, Bosch J. et al; COMPASS Investigators. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med 2017; 377 (14) 1319-1330
• 66 Bonaca MP, Bauersachs RM, Anand SS. et al. Rivaroxaban in peripheral artery disease after revascularization. N Engl J Med 2020; 382 (21) 1994-2004
• 67 Otto CM, Nishimura RA, Bonow RO. et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. Circulation 2021; 143 (05) e35-e71
• 68 Connolly SJ, Karthikeyan G, Ntsekhe M. et al; INVICTUS Investigators. Rivaroxaban in rheumatic heart disease-associated atrial fibrillation. N Engl J Med 2022; 387 (11) 978-988
• 69 Andreas M, Moayedifar R, Wieselthaler G. et al. Increased thromboembolic events with dabigatran compared with vitamin K antagonism in left ventricular assist device patients: a randomized controlled pilot trial. Circ Heart Fail 2017; 10 (05) e003709
• 70 Tektonidou MG, Andreoli L, Limper M. et al. EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis 2019; 78 (10) 1296-1304
• 71 Van Mieghem NM, Unverdorben M, Hengstenberg C. et al; ENVISAGE-TAVI AF Investigators. Edoxaban versus vitamin K antagonist for atrial fibrillation after TAVR. N Engl J Med 2021; 385 (23) 2150-2160
• 72 Dangas GD, Tijssen JGP, Wöhrle J. et al; GALILEO Investigators. A controlled trial of rivaroxaban after transcatheter aortic-valve replacement. N Engl J Med 2020; 382 (02) 120-129
• 73 Collet JP, Van Belle E, Thiele H. et al; ATLANTIS Investigators of the ACTION Group. Apixaban vs. standard of care after transcatheter aortic valve implantation: the ATLANTIS trial. Eur Heart J 2022; 43 (29) 2783-2797
• 74 Park DW, Ahn JM, Kang DY. et al; ADAPT-TAVR Investigators. Edoxaban versus dual antiplatelet therapy for leaflet thrombosis and cerebral thromboembolism after TAVR: the ADAPT-TAVR Randomized Clinical Trial. Circulation 2022; 146 (06) 466-479
• 75 Oliveri F, Bongiorno A, Tua L. et al. Direct oral anticoagulants or vitamin K antagonists after TAVR: insights from the ENVISAGE-TAVI AF and ATLANTIS trials. Thromb Haemost 2023; 123 (03) 362-365
• 76 Hart RG, Sharma M, Mundl H. et al; NAVIGATE ESUS Investigators. Rivaroxaban for stroke prevention after embolic stroke of undetermined source. N Engl J Med 2018; 378 (23) 2191-2201
• 77 Diener HC, Sacco RL, Easton JD. et al; RE-SPECT ESUS Steering Committee and Investigators. Dabigatran for prevention of stroke after embolic stroke of undetermined source. N Engl J Med 2019; 380 (20) 1906-1917
• 78 Geisler T, Keller T, Martus P. et al; ATTICUS Investigators. Apixaban versus aspirin for embolic stroke of undetermined source. NEJM Evid 2024; 3 (01) a2300235
• 79 Kamel H, Longstreth Jr WT, Tirschwell DL. et al; ARCADIA Investigators. Apixaban to prevent recurrence after cryptogenic stroke in patients with atrial cardiopathy: the ARCADIA randomized clinical trial. JAMA 2024; 331 (07) 573-581
• 80 Kleindorfer DO, Towfighi A, Chaturvedi S. et al. 2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association/American Stroke Association. Stroke 2021; 52 (07) e364-e467
• 81 Rivas A, Lauw MN, Schnabel RB, Crowther M, Van Spall HGC. Stroke and thromboembolism in patients with heart failure and sinus rhythm: a matter of risk stratification?. Thromb Haemost 2022; 122 (06) 871-878
• 82 Pandey AK, Eikelboom JW. Direct oral anticoagulant dosing in extremes of body weight: time to revisit the guidelines?. Thromb Haemost 2021; 121 (02) 118-120
• 83 Healey JS, Lopes RD, Granger CB. et al; ARTESIA Investigators. Apixaban for stroke prevention in subclinical atrial fibrillation. N Engl J Med 2024; 390 (02) 107-117
• 84 Kirchhof P, Toennis T, Goette A. et al; NOAH-AFNET 6 Investigators, NOAH-AFNET6 sites and investigators. Anticoagulation with edoxaban in patients with atrial high-rate episodes. N Engl J Med 2023; 389 (13) 1167-1179
• 85 McIntyre WF, Benz AP, Becher N. et al. Direct oral anticoagulants for stroke prevention in patients with device-detected atrial fibrillation: a study-level meta-analysis of the NOAH-AFNET 6 and ARTESiA trials. Circulation 2024; 149 (13) 981-988
• 86 Lopes RD, Granger CB, Wojdyla DM. et al. Apixaban vs aspirin according to CHA₂DS₂-VASc score in subclinical atrial fibrillation: insights from ARTESiA. J Am Coll Cardiol 2024; 84 (04) 354-364
• 87 Zhang Z, Si D, Zhang Q. et al. Prophylactic rivaroxaban therapy for left ventricular thrombus after anterior ST-segment elevation myocardial infarction. JACC Cardiovasc Interv 2022; 15 (08) 861-872
• 88 Abdelnabi M, Saleh Y, Fareed A. et al. Comparative study of oral anticoagulation in left ventricular thrombi (No-LVT Trial). J Am Coll Cardiol 2021; 77 (12) 1590-1592
• 89 Isa W, Hwong N, Mohamed Yusof A. et al. Apixaban versus warfarin in patients with left ventricular thrombus: a pilot prospective randomized outcome blinded study investigating size reduction or resolution of left ventricular thrombus. J Clin Prev Cardiol 2020; 9 (04) 150-154
• 90 Alcalai R, Butnaru A, Moravsky G. et al. Apixaban vs. warfarin in patients with left ventricular thrombus: a prospective multicentre randomized clinical trial. Eur Heart J Cardiovasc Pharmacother 2022; 8 (07) 660-667
• 91 Levine GN, McEvoy JW, Fang JC. et al; American Heart Association Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; and Stroke Council. Management of patients at risk for and with left ventricular thrombus: a scientific statement from the American Heart Association. Circulation 2022; 146 (15) e205-e223
• 92 Jenab Y, Sadeghipour P, Mohseni-Badalabdi. et al. Direct oral anticoagulants or warfarin in patients with left ventricular thrombus after ST-elevation myocardial infarction: a pilot trial and a prespecified meta-analysis of randomised trials. EuroIntervention 2024 (e-pub ahead of print).
• 93 Hosokawa K, Watanabe H, Taniguchi Y. et al; KABUKI Investigators. A multicenter, single-blind, randomized, warfarin-controlled trial of edoxaban in patients with chronic thromboembolic pulmonary hypertension: KABUKI trial. Circulation 2024; 149 (05) 406-409
• 94 Ferro JM, Coutinho JM, Dentali F. et al; RE-SPECT CVT Study Group. Safety and efficacy of dabigatran etexilate vs dose-adjusted warfarin in patients with cerebral venous thrombosis: a randomized clinical trial. JAMA Neurol 2019; 76 (12) 1457-1465
• 95 Maqsood M, Imran Hasan Khan M, Yameen M, Aziz Ahmed K, Hussain N, Hussain S. Use of oral rivaroxaban in cerebral venous thrombosis. J Drug Assess 2020; 10 (01) 1-6
• 96 Field TS, Dizonno V, Almekhlafi MA. et al; SECRET Investigators. Study of rivaroxaban for cerebral venous thrombosis: a randomized controlled feasibility trial comparing anticoagulation with rivaroxaban to standard-of-care in symptomatic cerebral venous thrombosis. Stroke 2023; 54 (11) 2724-2736
• 97 Chen X, Guo L, Lin M. Efficacy and safety of direct oral anticoagulants in cerebral venous thrombosis: meta-analysis of randomized clinical trials. Clin Appl Thromb Hemost 2024;30:10760296241256360
• 98 Ikesaka R, Siegal D, Mallick R. et al; Canadian Venous Thromboembolism Research Network (CanVECTOR). Thromboprophylaxis with rivaroxaban in patients with malignancy and central venous lines (TRIM-Line): a two-center open-label pilot randomized controlled trial. Res Pract Thromb Haemost 2021; 5 (04) e12517
• 99 Plessier A, Goria O, Cervoni JP. et al. Rivaroxaban prophylaxis in noncirrhotic portal vein thrombosis. NEJM Evid 2022; 1 (12) a2200104
• 100 Martin KA, Beyer-Westendorf J, Davidson BL, Huisman MV, Sandset PM, Moll S. Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: updated communication from the ISTH SSC Subcommittee on Control of Anticoagulation. J Thromb Haemost 2021; 19 (08) 1874-1882
• 101 Bikdeli B, Jiménez D, Garcia-Tsao G. et al; RIETE Investigators. Venous thromboembolism in patients with liver cirrhosis: findings from the RIETE (Registro Informatizado de la Enfermedad TromboEmbolica) registry. Semin Thromb Hemost 2019; 45 (08) 793-801
• 102 Qamar A, Vaduganathan M, Greenberger NJ, Giugliano RP. Oral anticoagulation in patients with liver disease. J Am Coll Cardiol 2018; 71 (19) 2162-2175
• 103 Eikelboom JW, Weitz JI. Direct oral anticoagulants in the very elderly. Thromb Haemost 2023; 123 (04) 377-379
• 104 Joosten LPT, van Doorn S, van de Ven PM. et al. Safety of switching from a vitamin K antagonist to a non-vitamin K antagonist oral anticoagulant in frail older patients with atrial fibrillation: results of the FRAIL-AF randomized controlled trial. Circulation 2024; 149 (04) 279-289
• 105 Khairani CD, Bejjani A, Assi A. et al. Direct oral anticoagulants for treatment of venous thrombosis: illustrated review of appropriate use. Res Pract Thromb Haemost 2024; 8 (04) 102424
• 106 Mazzolai L, Teixido-Tura G, Lanzi S. et al; ESC Scientific Document Group. 2024 ESC guidelines for the management of peripheral arterial and aortic diseases. Eur Heart J 2024; 45 (36) 3538-3700
• 107 Gornik HL, Aronow HD, Goodney PP. et al. 2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS guideline for the management of lower extremity peripheral artery disease: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. Circulation 2024; 149 (24) e1313-e1410
• 108 Li Z, Xu W, Wang L. et al. Risk of bleeding in liver cirrhosis receiving direct oral anticoagulants: a systematic review and meta-analysis. Thromb Haemost 2023; 123 (11) 1072-1088
• 109 Cohen AT, Sah J, Dhamane AD. et al. Effectiveness and safety of apixaban versus warfarin in venous thromboembolism patients with chronic kidney disease. Thromb Haemost 2022; 122 (06) 926-938

Publication History

Received: 14 September 2024

Accepted: 24 October 2024

Article published online:
18 November 2024